IN Brief:
- The FDA has approved Johnson & Johnson’s catheter platform for pulsed-field and radio-frequency ablation.
- CARTO integration combines mapping, imaging, catheter visualisation, contact-force feedback, and energy-index guidance.
- The system was introduced commercially in Europe before its phased United States rollout.
Johnson & Johnson has received US Food and Drug Administration approval for its Dual Energy THERMOCOOL SMARTTOUCH SF cardiac-ablation platform, which delivers pulsed-field and radio-frequency energy through one contact-force sensing catheter.
The system combines the Dual Energy THERMOCOOL SMARTTOUCH SF catheter with the TRUPULSE generator, allowing electrophysiologists to move between pulsed-field and radio-frequency energy during a procedure without changing the central treatment catheter. A phased United States rollout follows the platform’s earlier commercial introduction in Europe.
Integration with the CARTO ecosystem brings electro-anatomical mapping, ultra-high-density mapping, intracardiac ultrasound imaging, catheter visualisation, contact-force feedback, and PF or RF Index guidance into the same procedural architecture.
Radio-frequency ablation creates lesions through controlled thermal energy, whereas pulsed-field ablation applies high-voltage electrical pulses that disrupt cell membranes. Their different interactions with tissue allow energy to be selected according to anatomy, procedural strategy, and the region being treated.
The dual-energy platform is built around the existing THERMOCOOL SMARTTOUCH SF catheter family, which has been used in more than one million patients in the United States. Retaining a familiar point-by-point catheter format may reduce the workflow change involved in adding pulsed-field capability, although energy selection, mapping, and lesion assessment still require dedicated training.
Clinical support includes the SmartfIRE study of dual-energy focal ablation integrated with three-dimensional mapping. Procedure performance remains dependent on patient anatomy, operator technique, workflow adherence, contact, energy delivery, and the treatment strategy used in each case.
Cardiac ablation systems combine therapy delivery with a dense layer of sensing, imaging, timing, and control electronics. The catheter is only one part of an architecture that includes signal acquisition, position tracking, force measurement, ultrasound, energy generation, user interfaces, data storage, and multiple safety-monitoring channels.
A comparable convergence of electronics and biological measurement is appearing in CMOS-based sequencing platforms, where semiconductor sensing, fluidics, processing, and software are combined within one clinical instrument. In ablation, the physical output is therapeutic energy rather than sequence data, but dependable operation still rests on the coordination of several specialised subsystems.
Contact-force sensing influences both energy transfer and lesion formation. Insufficient contact may reduce treatment effectiveness, while excessive force can increase procedural risk, requiring accurate and stable measurements that can be presented without overloading the physician with competing information.
Mapping introduces another layer of system assurance because catheter position must be associated with anatomical geometry, electrical activity, ultrasound images, and previous ablation points. Registration drift, timing errors, sensor artefacts, or inconsistent coordinate handling can degrade the operating picture even when each subsystem performs correctly in isolation.
Supporting two energy modalities increases the control burden on the generator and catheter interface. The system must identify connected equipment, enforce valid operating states, monitor delivered energy, handle irrigation and contact data, and prevent an inappropriate mode or parameter combination from being used.
Those safeguards span hardware interlocks, embedded software, user-interface design, alarm management, and a documented safety architecture. Fault behaviour must remain predictable if a sensor fails, communication is interrupted, or the connected equipment does not match the selected procedure.
Long-term product control is equally demanding. Components, firmware, and host software need traceable change procedures, cybersecurity support, calibration controls, service documentation, and availability periods that reflect the operating life of installed hospital equipment.
An integrated mapping ecosystem can improve consistency by keeping catheter information, imaging, energy records, and procedure guidance within one environment, although it also creates dependencies between hardware generations and software versions. Updates must preserve validated interfaces across catheters, generators, mapping systems, imaging equipment, and hospital networks.
The approval extends dual-energy focal ablation into another major clinical market while preserving access to the European platform already in use. Its engineering development reflects a wider shift in medical electronics, where treatment performance increasingly depends on the quality of interfaces between sensors, software, spatial data, and controlled energy delivery.
